| Market Capitalization (Millions $) |
58 |
| Shares
Outstanding (Millions) |
55 |
| Employees |
106 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-60 |
| Cash Flow (TTM) (Millions $) |
79 |
| Capital Exp. (TTM) (Millions $) |
0 |
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited is a biotechnology company based in China. The company specializes in the development of novel therapies for the treatment of autoimmune and inflammatory diseases. Their research focuses on understanding the underlying mechanisms of these diseases and developing targeted therapies to address them.
Connect Biopharma has a proprietary platform called Immune Modulation Technology (IMT) that enables the discovery and development of highly selective and potent antibody-based therapeutics. The IMT platform utilizes a combination of genomics, proteomics, and data analytics to identify disease-specific targets and develop antibodies that specifically modulate these targets.
The company has a pipeline of potential drug candidates targeting various autoimmune diseases, including inflammatory bowel disease, atopic dermatitis, and asthma. Some of their lead candidates are currently in clinical trials, with promising results reported so far.
Connect Biopharma has also entered into partnerships with other pharmaceutical companies to further develop and commercialize their drug candidates. They have collaborations with global biopharmaceutical companies, academic institutions, and contract research organizations to accelerate the development and commercialization of their therapies.
Overall, Connect Biopharma Holdings Limited is an innovative biotech company focused on developing novel therapies for autoimmune and inflammatory diseases. Their proprietary technology and strategic partnerships position them well in the competitive biopharmaceutical industry.
Company Address: 12265 El Camino Real San Diego 92130 CA
Company Phone Number: 727-1040 Stock Exchange / Ticker: NASDAQ CNTB
|
1.32%